Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FURIN | P09958 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510213 | 0.98 | ALDH1A1 (0.55) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL4058730 | 0.96 | HPGD (0.56) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL510687 | 0.96 | HPGD (0.56) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL833489 | 0.94 | ALDH1A1 (0.58) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL15382502 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL3074898 | 0.87 | ACACB (0.50) | ALDH1A1KDM4EPARP10HPGDFAAH | |
| SCHEMBL8550317 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL8547301 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL8547307 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EPARP10HPGDCYP2A6 | |
| SCHEMBL8547303 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EPARP10HPGDCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | ALDH1A1 245/4885KDM4E 2693/4885PARP10 1496/4885 |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | ALDH1A1 2293/4885KDM4E 23/4885PARP10 1539/4885 |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | ALDH1A1 596/4885KDM4E 2170/4885PARP10 3983/4885 |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 570/4885KDM4E 2556/4885PARP10 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.